Nykode Therapeutics AS (5VB.F)
| Previous Close | 1.1140 |
| Open | 1.0810 |
| Bid | 1.0840 x N/A |
| Ask | 1.1170 x N/A |
| Day's Range | 1.0810 - 1.0810 |
| 52 Week Range | 1.0500 - 2.5860 |
| Volume | |
| Avg. Volume | 75 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireNykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq®1) in patients with HPV16-po
- GlobeNewswire
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
Updated survival data from Phase 2 trial (C-02) in advanced cervical cancer affirm prolonged benefits and indicate a synergistic treatment effect of Nykode’s VB10.16 and atezolizumab (Tecentriq®).New analysis closely mirrors previously reported positive outcome. At the time of the updated analysis, observation time for remaining patients was at least 24 months compared to at least 12 months at the previous reported outcome. Updated C-02 survival data support the accelerated development of VB10.1
- GlobeNewswire
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases
OSLO, Norway, March 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced key updates of the inverse vaccine platform with the potential to treat autoimmune diseases at the 7th Antigen-Specific Immune Tolerance Drug Development Summit in Boston. Nykode employs its unique technology platform to pioneer the field of inverse vaccines, with the potential to deve
